Thirty-day postoperative morbidity and mortality after temporal lobectomy for medically refractory epilepsy

J Neurosurg. 2018 Apr;128(4):1158-1164. doi: 10.3171/2016.12.JNS162096. Epub 2017 Jun 23.

Abstract

OBJECTIVE Temporal lobectomy is a well-established treatment modality for the management of medically refractory epilepsy in appropriately selected patients. The aim of this study was to assess 30-day morbidity and mortality after temporal lobectomy in cases registered in a national database. METHODS A retrospective cohort analysis was conducted using a multiinstitutional surgical registry compiled between 2006 and 2014. The authors identified patients who underwent anterior temporal lobectomy and/or amygdalohippocampectomy for a primary diagnosis of intractable epilepsy. Univariate and multivariable analyses with regard to patient demographics, comorbidities, operative characteristics, and 30-day outcomes were applied. RESULTS A total of 216 patients were included in the study. The median age was 38 years and 46% of patients were male. The median length of stay was 3 days and the 30-day mortality rate was 1.4%. Fourteen patients (6.5%) developed at least one major complication. Return to the operating room was observed in 7 patients (3.2%). Readmission within 30 days and discharge to a location other than home were available for 2011-2014 (n = 155) and occurred in 11% and 10.3% of patients, respectively. Multivariable regression analysis revealed that increasing age was an independent predictor of discharge disposition other than home and that male sex was a significant risk factor for the development of a major complication. Interestingly, the presence of the attending neurosurgeon and a resident during the procedure was significantly associated with decreased odds of prolonged length of stay (i.e., > 75th percentile [5 days]) and discharge to a location other than home. CONCLUSIONS Using a multiinstitutional surgical registry, 30-day outcome data after temporal lobectomy for medically intractable epilepsy demonstrates a mortality rate of 1.4%, a major complication rate of 6.5%, and a readmission rate of 11%. Temporal lobectomy is an extremely effective therapy for seizures originating there-however, surgical intervention must be weighed against its morbidity and mortality outcomes.

Keywords: 9th Revision; ACS = American College of Surgeons; ASA = American Society of Anesthesiologists; ASM = antiseizure medication; ATL = anterior temporal lobectomy; BMI = body mass index; CPT = Current Procedural Terminology; DVT = deep vein thrombosis; ICD-9 = International Classification of Diseases; LOS = length of stay; MI = myocardial infarction; NIS = Nationwide Inpatient Sample; NSQIP; NSQIP = National Surgical Quality Improvement Program; National Surgical Quality Improvement Program; PUF = Participant User File; TLE = temporal lobe epilepsy; UTI = urinary tract infection; amygdalohippocampectomy; epilepsy surgery; temporal lobectomy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Amygdala / surgery
  • Anterior Temporal Lobectomy / adverse effects*
  • Anterior Temporal Lobectomy / mortality
  • Cohort Studies
  • Drug Resistant Epilepsy / surgery*
  • Female
  • Hippocampus / surgery
  • Humans
  • Length of Stay
  • Male
  • Middle Aged
  • Neurosurgical Procedures / adverse effects*
  • Neurosurgical Procedures / mortality
  • Patient Readmission
  • Postoperative Complications / epidemiology*
  • Postoperative Complications / mortality*
  • Registries
  • Reoperation
  • Retrospective Studies
  • Sex Factors
  • Treatment Outcome
  • Young Adult